Samsung Biologics Secures 97.99% Stake in PolyPeptide Group Following Tender Offer

Samsung Biologics said its offeror, Samsung Peptide AG, secured 97.99% of PolyPeptide Group’s shares after the tender offer’s additional acceptance period ended on October 30, 2026. Samsung Peptide plans to squeeze out the remaining public shareholders and seek PolyPeptide’s delisting from the SIX Swiss Exchange. The definitive tender-offer result is expected on November 5, 2026.